 

Active ingredient: Bisoprolol Fumarate; Hydrochlorothiazide 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 
Design: Single-dose, two-way crossover in-vivo 

Strength: 10 mg/6.25 mg 

Subjects: Normal healthy males and females, general population. 

Additional Comments: 




______________________________________________________________________________ 

 

2. Type of study: Fed 
Design: Single-dose, two-way crossover in-vivo 

Strength: 10 mg/6.25 mg 

Subjects: Normal healthy males and females, general population. 

Additional comments: 




______________________________________________________________________________ 

 

Analytes to measure: Bisoprolol and Hydrochlorothiazide in plasma. 

 

Bioequivalence based on (90% CI): Bisoprolol and Hydrochlorothiazide 

 

Waiver request of in-vivo testing: 2.5 mg/6.25 mg and 5 mg/ 6.25 mg based on (i) acceptable 

bioequivalence studies on the 10 mg/6.25 mg strength, (ii) proportionally similar across all 

strengths, and (iii) acceptable in vitro dissolution testing of all strengths. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this 
product at this website. Please conduct comparative dissolution testing on 12 dosage units each 
of all strengths of the test and reference products. Specifications will be determined upon review 
of the application. 

 


